Goldman Sachs Maintains Neutral on Arrowhead as 2026 Pipeline Milestones Take Center Stage
Goldman Sachs has kept a Neutral rating and an $85 price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR), citing the company's recent move into the commercial phase following Redemplo approval for FCS and a slate of potential clinical catalysts in 2026. The bank highlighted a Phase 3 plozasiran SHASTA3/4 readout in severe hypertriglyceridemia exp…